Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-06-20
2008-03-18
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S036000, C514S037000, C514S038000, C514S039000, C514S040000, C514S152000, C514S154000
Reexamination Certificate
active
07345024
ABSTRACT:
The invention relates to hardly soluble antiphlogistic salts and antiphlogistic-antibiotic pharmaceutical preparations and their use. The hardly water soluble antiphlogistic antibiotics salts have as their cationic component one of the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and as their anionic component one of the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate. The antiphlogistic antibiotics salts are used in pharmaceutical preparations as controlled-release antibiotic/antibiotics drugs. The invention describes antiphlogistic-antibiotic pharmaceutical preparations for which mixtures in the solid state of aggregation are used, which are composed of an easily water soluble salt of gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicycline, oxytetracycline and/or rolitetracycline and at least one easily water soluble salt of ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and/or triamcinolone-21-sulfate and at least one inorganic and/or organic pharmaceutical adjuvant and which are used as permanent or temporary implants in the form of tablets and/or molded bodies.
REFERENCES:
patent: 3091572 (1963-05-01), Luedemann et al.
patent: 3536759 (1970-10-01), Jurando et al.
patent: 4291013 (1981-09-01), Wahlig et al.
patent: 4617293 (1986-10-01), Wahlig et al.
patent: 5459135 (1995-10-01), Golub et al.
patent: 25 17 600 (1975-12-01), None
patent: 32 48 328 (1984-06-01), None
patent: 697 07 927 (2002-04-01), None
patent: 0 420 600 (1991-04-01), None
patent: 354173 (1968-05-01), None
patent: 2 209 938 (1989-06-01), None
Renard, G. et al., “Efficacy and safety of a combination of indomethacin and gentamicin after cataract surgery”, J. Fr. Ophthalmol., 1996, vol. 19, No. 11, pp. 689-695.
Baeyens, V. et al., “Optimized release of dexamthasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections”, J. of Controlled Release, 1998, vol. 52, pp. 215-220.
Van Endt, J.J. et al., “A comparison of two ophthamlmic steroid antibiotic combinations after cataract surgery”, European J. of Ophthalmology, 1997, vol. 7, No. 2, pp. 144-148.
European Search Report for EP 03 01 1966, dated Jul. 29, 2003.
G. Renard, et al.; “Comparative study of a collagen corneal shield and a subconjuctival injection at the end of cataract surgery”, Journal of Cataract Refract. Surg. 1988, vol. 14, pp. 492-495.
Kühn Klaus-Dieter
Schnabelrauch Matthias
Vogt Sebastian
Heraeus Kulzer GmbH & Co. KG
Norris McLaughlin & Marcus PA
Peselev Elli
LandOfFree
Pharmaceutical preparation, method for its production as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical preparation, method for its production as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical preparation, method for its production as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3971124